The Warning Letter Brief

 FDA Regulatory Intelligence
Friday, August 28, 2026
Independent · not affiliated with or endorsed by the FDA. AI-generated with human-in-the-loop review, from public FDA Warning Letters — every letter links to its FDA source; verify before acting.
At a glance
2 new warning letters · 1 critical · 5 Stop-Use red flags to check.
1 Critical1 High2 full workups below
What matters this week
Your one move this week
Confirm every biologic you market has an approved BLA or active IND, and stop shipping any product that lacks one.
Floor-action deep dives — detailed below
This week's floor actions — one page for your shift leads
One action per letter, pulled from the full workups (the Table of Contents maps every letter). Print and hand out.
Start here: Confirm every biologic you market has an approved BLA or active IND, and stop shipping any product that lacks one.
This Week's Read
An editor's read across this week's letters — what FDA is prioritizing, and the one move that matters.

FDA is targeting two basics: import safety and drug approval. The Critical letter hits a biologic marketer. R3 Medical sold unapproved drugs and unlicensed biologics with no BLA or IND. A BLA is a Biologics License Application. An IND is an Investigational New Drug application. The food letter hits an importer with no FSVP, a Foreign Supplier Verification Program. The top action: if you market biologics, confirm every product has FDA approval before you sell.

How to read this brief
What this covers. Built from the FDA warning letters posted this week — this issue covers the drugs & biologics and food centers. The data-integrity and quality-system lessons transfer to any dosage form — each detailed letter includes an oral-solid-dose and a topical/liquid translation. Biologics-specific risks (single-use systems, cold chain, comparability, viral safety, live-cell handling) are out of current scope.
Severity ranks (per letter)
  • Critical Goes straight to patient safety or the integrity of FDA's evidence: a sterility failure, data integrity/falsification, a quality-unit breakdown, an active import alert, or a marketed product shown defective by actual test results (FDA's or the firm's own) — not the routine “adulterated” wording the law attaches to every cGMP letter.
  • High A serious, systemic CGMP/QSR gap (unvalidated process, no supplier qualification, complaint/CAPA failure) that is still contained in scope — no specific patient or lot shown harmed yet.
  • Moderate A real but bounded deficiency — usually procedural, documentation, or a one-time lapse — that signals weak control without immediate product or patient exposure.
  • Low An isolated administrative or labeling-level issue, with no shown impact on product quality or patient safety.
  • Listed Not risk-graded. A letter outside manufacturing/quality scope (marketing, labeling, or unapproved-drug claims only) or beyond this run's deep-dive budget — indexed in full but not deep-read. It appears ONLY as its Table of Contents line, with a link to the source FDA letter; it does not get its own page below.
These ranks reflect FDA's enforcement severity — not the risk to YOUR site. Calibrate each one to your own products, patients, and risk tolerance. When your judgment differs from ours, move the item up a level, never down.
KPI severity (what to do)
  • Stop-Use Halt and quarantine now. The risk is to product safety or distribution, not paperwork.
  • Escalate Raise to the Quality Review Board for a decision. Serious, but not an immediate halt.
  • Monitor Trend it over time. Watch the signal; no immediate action needed.
Other terms
  • Leading A measure that warns you before a gap happens (the kind we prefer). Lagging only confirms a problem after the fact.
  • Quality Review Board Your quality-governance forum (QRB), where escalated issues are decided and owned.
  • Daily Production Meeting Your daily production huddle, where fast, daily-cadence checks are run on the floor.
Confidence tags (on interpretation)
  • FDA-stated The FDA letter says this directly — it is a fact, not our interpretation.
  • Strong inference Very likely but NOT stated by FDA — our reading of the facts (roughly 60–80% sure).
  • Plausible A real possibility, not stated by FDA (roughly 30–60% sure). Confirm before you rely on it.
  • Speculative A weaker possibility (under ~30%), flagged so you can check — not a conclusion.
Table of Contents
All 2 letters in this issue · grouped by sector · every entry links to the FDA-published letter — nothing in this issue is dropped. The manufacturing- and quality-system letters — those citing CGMP, QSR, sterility or aseptic processing, data integrity, or a food-safety program (FSVP, preventive controls, HACCP) — earn a full floor-action workup. Where several letters cite near-identical findings, they are analyzed together and presented as one sweep summary rather than repeating the same workup; every letter is still listed and linked. Letters citing only marketing, labeling, or unapproved-drug claims are listed in full but not deep-read — the call is made on the letter's own text, so a letter whose FDA subject line reads “unapproved drugs” still earns a workup when the text cites CGMP or sanitation findings.
Drugs & Biologics
1 letter detailed in full
Critical
R3 Medical Companies (Bello Bio, LLC / Regen Suppliers, LLC)
Biologic · Scottsdale, AZ · Center for Biologics Evaluation and Research (CBER) · Posted 08/25/2026 · Issued 08/14/2026 · View FDA letter →
📌 Here's what you need to know (FDA-stated)
  • FDA found four products — ReBellaWJ, ReBellaXO, ReBellaXOL, ReBellaCB — are unlicensed biologics and unapproved new drugs distributed in interstate commerce.
  • FDA explicitly warned that seizure and/or injunction may occur without further notice.
  • FDA found the same CEO was warned about the same conduct in May 2019 — this is a documented repeat violation.
  • FDA found sterility testing samples were frozen before testing, which may destroy microbial content and render results unreliable.
  • FDA found 483 responses inadequate, with no plan to address inventory still distributed and within expiry.
✅ Here's what you need to check for
  • ☐ Do any of your products or services involve umbilical cord-derived materials, exosomes, or cord-blood products marketed for disease treatment or tissue regeneration?
    If you can't confirm this: Stop distribution immediately. These product types require a BLA or active IND to be legally marketed in the US. Contact regulatory counsel within 24 hours to assess your regulatory status before any further sales or distribution.
  • ☐ Can you confirm your aseptic manufacturing process has been fully validated with documented media fills and challenge studies?
    If you can't confirm this: Quarantine all products manufactured under unvalidated aseptic conditions. Do not release new lots until a process validation protocol is executed and reviewed by your quality unit. Open a CAPA with the VP of Manufacturing as owner, due within 30 days.
  • ☐ Does your sterility testing protocol require that samples be tested without prior freezing, to preserve any microbial content that may be present?
    If you can't confirm this: Halt sterility testing under the current freeze-thaw method. Work with your micro lab to revise the sampling and testing procedure so samples reach the testing lab without freezing. Retrospectively assess the value of sterility data already collected using the frozen-sample method.
  • ☐ Do your donor eligibility screening documents include specific criteria and qualifiers for Transmissible Spongiform Encephalopathy (TSE), including Creutzfeldt-Jakob disease (CJD and vCJD)?
    If you can't confirm this: Immediately revise your Donor Eligibility Criteria to add TSE/CJD/vCJD screening questions per 21 CFR 1271.75(a)(1)(iv) and FDA's August 2007 donor eligibility guidance. Do not process new donors until the revised criteria are approved by your quality unit.
  • ☐ Do your products carry an expiration date supported by actual stability data generated under a written, approved stability program?
    If you can't confirm this: Quarantine any product lot whose expiration date is not backed by stability data. Do not assign or reuse an expiration date without a written stability protocol and supporting data. Open a CAPA with QA as owner to design and initiate a stability program within 60 days.
Check the box next to anything you can't confidently confirm today — each is a gap; take the action shown beneath it. Contain first if product or patient safety could be affected.A starting-point self-check, not a substitute for your own gap assessment.
🔁 Run a different dosage form? Same lesson on your line
  • Oral solid dose (tablets, capsules): The core failure here is marketing a product without regulatory authorization and without validated manufacturing. For OSD: confirm every product in your portfolio has an approved NDA, ANDA, or an active IND before distribution. Confirm your process validation covers all critical quality attributes (identity, strength, purity) per your approved filing. Rule: 21 CFR 211.100(a); 21 U.S.C. § 355(a).
  • Topical / semisolid / liquid: The sterility-testing flaw (freeze-thaw before testing) is directly relevant to preserved aqueous topicals. Confirm your bioburden and preservative-efficacy (PET) samples are never frozen before testing. Confirm your micro-limits SOP references USP <61>/<62> and names objectionable organisms for your product type. If your product contains water, confirm loop sanitization cadence is documented and limits are validated. Rule: 21 CFR 211.160(b).
The finding above is form-specific. Here's the same failure mode translated to your line.
👣 Gemba walks you can do right now
  • Aseptic processing area — biological safety cabinet or cleanroom filling line — Watch whether operators perform each step of the aseptic process exactly as written in a validated protocol. Look for any deviation from the procedure — especially any unqualified intervention, gown breach, or equipment movement — that is not immediately documented as an intervention record.
  • QC microbiology lab — sample receipt and testing station — Confirm that sterility test samples arrive at the lab without any freeze-thaw history. Check the sample log for temperature records at receipt. Watch whether the analyst documents sample condition before starting any test.
  • Donor eligibility and incoming materials area — Pull the most recent five donor eligibility records. Confirm each one has a completed TSE/CJD/vCJD screening section with a qualifier and a reviewer signature. Check whether the effective-date of the criteria document in use matches the current approved version.
Go to the floor and see the real work — that's where the gap between the SOP and reality shows up.
🗣️ Shift huddle — hand each set to the right supervisor
Give each supervisor only the questions for their area — pick ONE to ask at the next huddle, don't run them all. They ask their operators and listen; the people closest to the work see it first. Skip any tagged for a dosage form you don't run.
Hand to your QC / Micro Lab supervisor
  • Ask: When you receive a sterility test sample, what do you do if it looks like it was ever frozen or partially thawed before it got to you?
    🚩 Flag if you hear: Operator says they test it anyway, or there is no step to check or record the sample's temperature history at receipt.
    → Then: Hold the sample and the associated lot now; tell QA on call; open a deviation today.
Hand to your QA supervisor
  • Ask: When a corrective action from a 483 response is marked 'closed,' what documentation do you require before you close it — and does that include an effectiveness check?
    🚩 Flag if you hear: Operator says CAPAs are closed based on completion of the action alone, with no effectiveness check or with a check performed against a revised target date instead of the original one.
    → Then: Hold the closure; tell QA on call; reopen the CAPA and escalate to QA leadership today.
Hand to your Warehouse / Materials supervisor
  • Ask: When a new donor tissue lot arrives, what paperwork do you check before you accept it into your inventory? Sterile / aseptic filling — biological / HCT/P products only
    🚩 Flag if you hear: Operator cannot name a donor eligibility document or does not know what TSE screening is, or says no eligibility document is required before tissue is accepted.
    → Then: Quarantine the lot now; tell QA on call; open a deviation today.
Hand to your Production / Aseptic Filling supervisor
  • Ask: If something goes wrong during aseptic filling — like a gown touches an open container — what do you do next, and where do you write it down? Sterile / aseptic filling only
    🚩 Flag if you hear: Operator says they would continue without stopping or documenting, or does not know the intervention recording step.
    → Then: Stop the filling run; tell QA on call; open a deviation before the batch is released.
💡 Things you may not have thought of
  • The freeze-thaw sterility-testing flaw means every 'passing' sterility result already in the batch record may be scientifically unreliable — retrospective lot disposition decisions hinge on this gap. Strong inference
  • The multi-entity corporate structure (Bello, Regen, R3 Stem Cell, R3 Anti-Aging) means enforcement action against one entity may not stop distribution by the others unless all are addressed simultaneously. Strong inference
Lessons from this letter. Anything not tagged “FDA-stated” is PharmTech.AI interpretation, not an FDA finding.
📊 Metrics you need to monitor for prevention
  • Stop-Use Active lots shipped without BLA or IND — weekly count — Flag if: Any lot shipped or transferred without BLA/IND in effect Daily Production Meeting
  • Stop-Use Sterility samples tested without prior freeze — % compliance — Flag if: Any sample frozen before sterility testing is completed Quality Review Board
  • Stop-Use Aseptic process steps with approved validation — % complete — Flag if: Any aseptic manufacturing step without a completed, QU-approved validation package Quality Review Board
  • Escalate Donor records with TSE screening completed — % of total — Flag if: Any donor record missing TSE/CJD/vCJD screening documentation Quality Review Board
  • Escalate Lots with expiry not supported by stability data — count — Flag if: Any lot in distribution with an expiry date lacking supporting stability data Quality Review Board
  • Escalate 483-response CAPAs with effectiveness check at +90 days — % — Flag if: Any CAPA closed without a QU-signed effectiveness check at +90 days from original committed date Quality Review Board
Full metric specs ship with every edition as a CSV (letter, KPI, trigger, cadence, data source, owner, denominator) — built to drop into your QMS or BI tool.
📋 SOP checks you must verify are in place
  • Aseptic Process Validation SOP: Confirm the SOP requires a completed, QU-approved media fill before any new aseptic manufacturing process is used to produce product for distribution. (21 CFR 211.113(b))
  • Sterility Testing SOP: Confirm the SOP explicitly prohibits freezing samples prior to sterility testing and requires documentation of sample temperature history at lab receipt. (21 CFR 211.160(b))
  • Donor Eligibility Determination SOP: Confirm the SOP includes a required field for TSE/CJD/vCJD screening with explicit qualifier language per 21 CFR 1271.75(a)(1)(iv) and the August 2007 FDA donor eligibility guidance. (21 CFR 1271.75(a)(1)(iv))
  • Quality Unit Responsibilities SOP: Confirm the SOP defines written quality unit responsibilities including authority to approve or reject drug products and a procedure for handling all written and oral complaints. (21 CFR 211.22(d))
Food
1 letter detailed in full
High
Vargas Produce LLC
Food · McAllen, TX · Office of Inspections and Investigations · Posted 08/25/2026 · Issued 07/27/2026 · View FDA letter →
📌 Here's what you need to know (FDA-stated)
  • FDA found Vargas Produce had no FSVP at all — for any imported food, any supplier.
  • The firm did not respond to the FDA Form 483a issued June 18, 2026.
  • A prior inspection on February 25, 2025, preceded this one — the violation is a repeat.
  • FDA threatened DWPE under Import Alert 99-41, which would halt all covered imports.
  • Named import products include Cookies, a redacted Soft Drink, and Spicy Potato Chips.
✅ Here's what you need to check for
  • ☐ Do you import food from any foreign supplier — and does your FSVP file exist as a written document covering every one of those suppliers?
    If you can't confirm this: Quarantine all incoming shipments from any supplier not covered by a written FSVP. Open a CAPA immediately with a named owner and a 15-working-day target to draft the missing FSVP elements. Do not release those shipments until the FSVP is in place and reviewed.
  • ☐ Have you verified your foreign suppliers' food-safety performance within the past 12 months using an approved verification activity (audit, testing, review of food-safety records)?
    If you can't confirm this: Put all unverified supplier lots on hold. Schedule and document a supplier verification activity (such as an on-site audit or lot-by-lot testing) before releasing any held product. Record the verification outcome in your FSVP file.
  • ☐ If FDA issued you a Form 483a or other written observation, did you respond in writing within 15 working days?
    If you can't confirm this: Draft and send a written response immediately, even if corrections are not yet complete. Explain the delay and commit to a specific completion date. Route the response through your regulatory or compliance lead before sending.
  • ☐ Does your FSVP cover every food-commodity type and every foreign supplier you use — including any new suppliers added in the last 12 months?
    If you can't confirm this: Map all active import purchase orders to your FSVP supplier list. For any supplier not on the list, halt new orders and open a corrective action to add them before the next shipment.
  • ☐ Are you aware of Import Alert 99-41, which allows FDA to detain your imports without physical examination if your FSVP is non-compliant?
    If you can't confirm this: Brief your logistics and purchasing teams on DWPE risk today. Identify all in-transit shipments and assess whether FSVP coverage exists for each. Contact your FDA compliance officer or a regulatory consultant to assess your current exposure.
Check the box next to anything you can't confidently confirm today — each is a gap; take the action shown beneath it. Contain first if product or patient safety could be affected.A starting-point self-check, not a substitute for your own gap assessment.
🔁 Run a different dosage form? Same lesson on your line
  • Oral solid dose (tablets, capsules): FSVP is a food-sector program, but OSD firms share the same supplier-qualification gap risk. Confirm your supplier qualification procedure requires a written assessment for every API and excipient supplier before first use. Verify records exist for all active suppliers. Rule: 21 CFR 211.84.
  • Topical / semisolid / liquid: FSVP is a food-sector program, but topical and liquid manufacturers share the same foreign-supplier gap risk. Confirm every foreign raw-material supplier has a written qualification on file, including a hazard assessment and a verification activity completed within the past 12 months. Rule: 21 CFR 211.84.
The finding above is form-specific. Here's the same failure mode translated to your line.
👣 Gemba walks you can do right now
  • Receiving dock / incoming freight area — Imported food shipments arriving without any FSVP file attached to the delivery record. Check whether the receiving team can locate a written FSVP for the supplier on the bill of lading before the goods are accepted.
  • Purchasing / procurement office or shared drive — A complete list of all foreign suppliers matched to FSVP documents. Spot-check three suppliers at random — confirm each has a written hazard analysis, a supplier evaluation, and a verification activity record no older than 12 months.
  • Regulatory or compliance file storage (physical or electronic) — Whether FSVP records are organized by supplier and product, dated, signed, and retrievable within minutes. Missing files, unlabeled folders, or records with no revision date are red flags.
Go to the floor and see the real work — that's where the gap between the SOP and reality shows up.
🗣️ Shift huddle — hand each set to the right supervisor
Give each supervisor only the questions for their area — pick ONE to ask at the next huddle, don't run them all. They ask their operators and listen; the people closest to the work see it first. Skip any tagged for a dosage form you don't run.
Hand to your Warehouse / Materials supervisor
  • Ask: When a shipment arrives from a foreign supplier, what paperwork do you check before accepting it? Is there ever a supplier we receive from that doesn't have a food-safety file on record?
    🚩 Flag if you hear: Operator says they accept shipments based on the purchase order alone — no FSVP file check.
    → Then: Hold the shipment now; tell QA on call; open a deviation today.
  • Ask: Has any new supplier sent us product in the last 90 days? Did we have an approved food-safety file for them before that first shipment arrived?
    🚩 Flag if you hear: A new supplier shipped before its FSVP was approved.
    → Then: Quarantine affected lots now; tell QA on call; open a deviation today.
Hand to your QA supervisor
  • Ask: If you had to pull the FSVP file for any one of our foreign suppliers right now, how long would that take? When was the last verification activity completed for our top three suppliers?
    🚩 Flag if you hear: Staff cannot locate an FSVP file in under 5 minutes, or the last supplier verification is more than 12 months ago.
    → Then: Hold new orders from that supplier; tell QA on call; open a CAPA today.
💡 Things you may not have thought of
  • A DWPE listing can strand in-transit shipments immediately — not just future orders — creating a cash-flow crisis before a correction plan is even drafted. Strong inference
  • Surviving a second inspection without correcting a violation signals to FDA that voluntary compliance is unlikely, accelerating the path to import refusal. Strong inference
Lessons from this letter. Anything not tagged “FDA-stated” is PharmTech.AI interpretation, not an FDA finding.
📊 Metrics you need to monitor for prevention
  • Stop-Use % active foreign suppliers with completed FSVP — Flag if: Any active supplier missing a completed FSVP file. Quality Review Board
  • Stop-Use Days past 15-working-day FDA response deadline — Flag if: Response not submitted by end of working day 15. Daily Production Meeting
  • Escalate Suppliers with current (≤12-month) verification on file — Flag if: Any active supplier with no completed verification activity in the past 12 months. Quality Review Board
  • Escalate New suppliers onboarded without pre-shipment FSVP — Flag if: Any new supplier onboarded without a pre-shipment FSVP on file. Quality Review Board
  • Escalate CAPA effectiveness confirmed at 90 and 180 days — Flag if: Any CAPA item lacking a documented, independent effectiveness check at the 90-day mark. Quality Review Board
Full metric specs ship with every edition as a CSV (letter, KPI, trigger, cadence, data source, owner, denominator) — built to drop into your QMS or BI tool.
📋 SOP checks you must verify are in place
  • FSVP Program Procedure: Confirm the SOP requires a written FSVP to be completed for every foreign supplier before the first shipment is received. (21 CFR 1.502(a))
  • New Supplier Onboarding Procedure: Confirm the procedure includes a gate — no purchase order is issued to a new foreign supplier until the FSVP file is approved by the QA function. (21 CFR 1.503)
  • Supplier Verification Procedure: Confirm the SOP defines the type and frequency of verification activities (audit, testing, or records review) for each hazard category and sets a maximum interval of 12 months. (21 CFR 1.506)
  • Regulatory Correspondence Procedure: Confirm the SOP requires a written response to any FDA 483a or warning letter within 15 working days, with a named owner and an escalation path to senior management. (21 CFR part 1, subpart L)
This is one agent. Here's what else it does for your team.
You're reading the FDA edition. The same engine reads the rest of your regulatory world — and puts your people through the failures before they happen.
Other agencies, same brief. OSHA, EPA, and seven more agencies, on the same cadence — one view of your site's whole regulatory exposure. See the agencies we cover →
An agent pointed at your own site. We build a private version that reads your inspection history, 483s, and internal signals — not just public letters. Your data stays segregated, is never used to train shared models, and the system ships with a CSA-style validation rationale for your quality file. Ask about a private agent →
Put your team in the drill. Timed crisis-simulation software your leads run on a clock, without an outside facilitator. First scenario: a wildfire plant shutdown, built from a real one; further scenarios in development. Preview the crisis sim →
Forward this to the one person on your quality team who should be reading it. New sectors ship first to current subscribers.
PharmTech.AI by Aligned Executive Solutions, Inc. · Former FDA-inspected QA leadership · cGMP & quality systems
Report verified for accuracy by PharmTech.AI.
AI-generated with human-in-the-loop review, from public FDA Warning Letters — each letter linked to its FDA source. FDA-stated facts are kept separate from clearly labeled PharmTech.AI interpretation; product identifications for redacted letters are inferences with confidence + basis, not FDA findings. Warning letters may be rescinded or closed out — verify current status at fda.gov before relying on this. Corrections: mike@aesresults.com. Informational thought-leadership, not legal or regulatory advice.
PharmTech.AI™ is a trademark of Aligned Executive Solutions, Inc. All other names and marks are the property of their respective owners.
© 2026. All rights reserved.